Tests JADE101 against placebo in adults with IgA nephropathy
Tests JADE101 injections against placebo in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Key facts
- Where
- Arvada, Atlanta, Katy, and Lauderdale Lakes, United StatesSee the 4 sites
- Phase
- Phase 3
Where in United States
- ArvadaArvada, United StatesTaking people
- AtlantaAtlanta, United StatesTaking people
- KatyKaty, United StatesTaking people
- Lauderdale LakesLauderdale Lakes, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jade Biosciences, Inc.
- Trial code
- NCT07902817EU 2026-527177-11-00
- Record updated
- 3 November 2026
- Original description
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.Read full original descriptionShow less
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of JADE101 Administered Subcutaneously in Participants With Immunoglobulin A Nephropathy (The EVERGREEN Study)
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.
Inclusion: Adult participants with biopsy-confirmed primary IgAN; UPCR ≥0.75 g/g or 24-hour protein excretion ≥1 g/day, as measured from an adequately collected 24-hour urine sample; eGFR ≥30 mL/min/1.73 m²; Stable and maximally tolerated doses of ACEi and/or ARB according to standard of care and applicable guidelines for at least 12 weeks prior to the initial screening visit.
Exclusion: Receipt of systemic immunosuppressive agents or procedures (including corticosteroids, oral immunosuppressive agents, protocol-specified herbal medicines, or tonsillectomy) within the protocol-defined washout period; Previous or current treatment (including in a prior clinical trial) with anti-APRIL biologics, anti-CD38 therapy, or anti-CD20 therapy; Anti-APRIL biologics; Anti-CD38 therapy; Anti-CD20 therapy; Receipt of an investigational compound or complement inhibitor within 30 days or 5 half-lives (whichever is longer) prior to screening; Presence of or history of nephrotic syndrome, defined as 24-hour urine protein >3.5 g/day with concurrent hypoalbuminemia; Any chronic infectious disease (e.g., chronic urinary tract infection, chronic sinusitis, bronchiectasis, active pulmonary tuberculosis, or systemic tuberculosis); Serum IgG level <6 g/L (<600 mg/dL); Other protocol-defined inclusion and exclusion criteria may apply; Secondary forms of IgAN, or ongoing IgA vasculitis (Henoch-Schönlein purpura) with systemic involvement requiring immunosuppressive treatment; Known or clinically suspected rapidly progressive glomerulonephritis (RPGN); Body weight <40 kg or morbid obesity.